How Small Supply Issues Can Disrupt Healthcare: Lessons from a Prep Pad Recall and a Hurricane
A single storm damaged IV bag supply for months, 174 million alcohol prep pads got recalled over a rare bacterium, and tariffs quietly reshaped where the world's medical gloves get made: what is actually moving in medical disposables beyond the market-size numbers.
No one worries about running out of alcohol prep pads or IV bags until they actually run out. That is more or less what happened across 2025 and 2026, when a hurricane, a contamination scare, and a tariff fight each showed how little slack exists in the supply of the simplest, cheapest products in healthcare. This piece sets the market-sizing numbers in our companion report aside and focuses on what is actually moving in trade policy, supply chain resilience, and regulation across the past two years.
One Damaged Factory, Months of Rationing
The clearest lesson in concentrated manufacturing risk came from an IV fluid shortage that started when Hurricane Helene damaged a major Baxter manufacturing site. Hospitals spent months rationing IV saline and adjusting clinical protocols before the FDA announced in August 2025 that the shortage had been resolved. The episode was a reminder that even a high-volume, low-margin product like a bag of saline solution can become scarce almost overnight when a large share of national supply runs through a small number of manufacturing sites.
What makes this risk persistent rather than a one-time event is that the economics pushing manufacturing toward concentration, scale efficiency, thin margins on basic disposables, have not changed. A hospital system that wants to protect itself from the next supply disruption has to weigh that against paying more for diversified sourcing on a product category where margins are already thin enough that few buyers are willing to pay a premium for resilience they may never need.
A Recall on a Scale That Gets Attention
If the IV saline shortage showed what happens when supply runs short, Cardinal Health's March 2026 recall of roughly 174 million Webcol alcohol prep pads showed what happens when a quality failure hits a product used in nearly every clinical encounter. The company pulled the pads nationwide after testing found a rare bacterium that could cause contamination, a reminder that a product simple enough to be taken for granted still carries real infection control risk if something goes wrong in manufacturing.
Recalls at this scale rarely make headlines for long, but they tend to move quietly through hospital purchasing departments for months afterward, prompting a fresh look at backup suppliers for products that buyers had stopped thinking about precisely because they rarely go wrong.
Tariffs Are Redrawing Who Makes the World's Gloves
Trade policy has become one of the more consequential forces in medical disposables, even though it has nothing to do with clinical need. When the US finalized higher tariffs on a range of Chinese-made medical products in 2025, shares of Malaysian glove manufacturers surged, since Malaysia already supplied a large share of the world's disposable gloves and stood to gain further as US buyers diversified away from Chinese suppliers. The shift illustrates how a trade decision made for reasons unrelated to healthcare can still reorganize global manufacturing capacity for a product every hospital in the world uses every day.
This kind of sourcing shift is slower than the policy change that triggers it. Switching an established glove supplier means requalifying a new manufacturing site, testing product consistency, and renegotiating contracts, so the full effect of a tariff decision typically plays out over one to two years rather than immediately.
| Date | Development | Category |
|---|---|---|
| Apr 2025 | Malaysian glove makers gain as US finalizes higher China tariffs | Trade policy |
| Aug 2025 | FDA declares IV saline solution shortage resolved | Supply chain |
| Mar 2026 | Cardinal Health recalls 174 million alcohol prep pads | Quality/recall |
Source: The Star (Apr 4, 2025); American Hospital Association (Aug 11, 2025); FDA (Mar 2026).
Distributors Are Narrowing Their Focus, Not Broadening It
While manufacturing capacity gets reshaped by tariffs and supply shocks, distribution has been moving the opposite direction: toward narrower, more focused businesses rather than broad product empires. Owens & Minor completed the sale of its Products & Healthcare Services business, which includes a range of medical disposables, to private equity firm Platinum Equity at the end of 2025, letting Owens & Minor concentrate on its core distribution operations while giving the divested business a standalone owner focused specifically on running it.
At the manufacturing end, BD's January 2026 decision to invest $110 million in its Nebraska site to expand prefillable syringe production points to a related but distinct trend: syringe makers increasingly chasing the more specialized, higher-value end of the category, driven by demand from injectable biologic drugs, rather than competing purely on volume in commodity syringes.
Related Vectomat Insights Coverage
This article provides editorial and R&D context only. For full market sizing, segmentation, regional share, competitive benchmarking and forecasts through 2035, see the companion Medical Disposables Market Report.